US 11,911,151 B1
Analyte monitoring device and methods of use
Thomas A. Peyser, Menlo Park, CA (US); and Adam Heller, Austin, TX (US)
Assigned to Abbott Diabetes Care Inc., Alameda, CA (US)
Filed by ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed on Oct. 6, 2022, as Appl. No. 17/938,450.
Application 17/938,450 is a continuation of application No. 17/715,922, filed on Apr. 7, 2022.
Application 17/715,922 is a continuation of application No. 17/526,645, filed on Nov. 15, 2021, granted, now 11,363,975, issued on Jun. 21, 2022.
Application 17/526,645 is a continuation of application No. 17/461,215, filed on Aug. 30, 2021, granted, now 11,272,867, issued on Mar. 15, 2022.
Application 17/461,215 is a continuation of application No. 17/207,347, filed on Mar. 19, 2021, granted, now 11,103,165, issued on Aug. 31, 2021.
Application 17/207,347 is a continuation of application No. 16/355,919, filed on Mar. 18, 2019, granted, now 10,952,652, issued on Mar. 23, 2021.
Application 16/355,919 is a continuation of application No. 14/747,583, filed on Jun. 23, 2015, granted, now 10,231,654, issued on Mar. 19, 2019.
Application 14/747,583 is a continuation of application No. 13/283,562, filed on Oct. 27, 2011, granted, now 9,066,697, issued on Jun. 30, 2015.
Application 13/283,562 is a continuation of application No. 11/265,787, filed on Nov. 1, 2005, granted, now 8,974,386, issued on Mar. 10, 2015.
Int. Cl. A61B 5/1486 (2006.01); A61B 5/1473 (2006.01); A61B 5/145 (2006.01); A61B 5/00 (2006.01)
CPC A61B 5/14532 (2013.01) [A61B 5/0002 (2013.01); A61B 5/0031 (2013.01); A61B 5/1473 (2013.01); A61B 5/14546 (2013.01); A61B 5/14865 (2013.01); A61B 5/4839 (2013.01); A61B 5/742 (2013.01); A61B 5/7445 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A system, comprising:
an transcutaneous glucose sensor having a proximal portion configured to remain above a skin surface of a user and a distal portion positionable beneath a skin surface of a user in a subcutaneous space, wherein the transcutaneous glucose sensor is configured to generate signals at a working electrode over a sensor session having a length of at least five days including a first day, a second day, a third day, a fourth day, and a final day, the generated signals associated with an in vivo glucose concentration; and
a sensor control unit comprising at least one contact in electrical communication with the proximal portion of the sensor, the sensor control unit configured to receive the generated signals and convert the generated signals to glucose concentration data using calibration data, the sensor control unit further comprising a transmitter configured to communicate the glucose concentration data to a receiver unit;
wherein the glucose concentration data has:
a first accuracy corresponding to the first day of the sensor session,
a second accuracy corresponding to the second day of the sensor session, and
a third accuracy corresponding to the fourth day of the sensor session;
wherein the second accuracy is higher than the first accuracy, the third accuracy is higher than the second accuracy.